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Summary
Objectives Dissemination of tumour cells occurring both
spontaneously or caused by diagnostic biopsy procedures is the most
serious complication of solid malignancies. In the present work we focus
on local tumour spread and how this complication of cancer disease can
be counteracted.
Design From a cohort of 864 breast cancer patients we selected those
who died of their primary cancer and those who died because of a
simultaneouslyexisting cardio-cerebral-vascular disease (CCVD) and were
exposed to anticoagulants.
Setting The study was based on breast cancer patients diagnosed at
Karolinska University Hospital during 1991 (n = 519) and 1997–1998
(n = 345).
Main outcome measures Axillary lymph node metastasis (ALNM)
and survival of breast cancer patients with concurrent CCVD.
Results Breast cancer patients belonging to the group that died of
CCVD showed ALNM at the time of tumour diagnosis in 27% of the cases
compared with 68% diagnosed in the group that died of their breast cancer
(p<0.0001). Likewise we observed a highly signiﬁcant (p <0.0001)
difference in mean survival time with an average of 102 months in the
group of breast cancer patients who died of CCVD and an average of 61
months in the group who died of breast cancer.
Conclusion The data presented herein indicate that breast cancer
patients regularly involved in treatment with anticoagulants because of
simultaneously existing CCVD develop ALNM signiﬁcantly less frequently
and have an increased average survival time compared with breast cancer
patients not suffering from CCVD.
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RESEARCH
1Introduction
There is a general agreement that more than 90% of
cancer patient deaths are related to distant metas-
tases. This means that not only the primary
tumour itself but the disseminated cells of the
tumour determine the fate of the vast majority of
cancer patients. Thus, in order to signiﬁcantly
decrease the death rate of cancer patients one of
the urgent tasks in the ﬁeld of cancer research is
to develop procedures efﬁciently reducing the risk
of tumour cell dissemination.
It is also well known that malignant solid
tumours behave signiﬁcantly different regarding
clinical aggressiveness and the occurrence of clini-
cally detectable metastases. A few commonly
known examples are pancreatic carcinomas with
a high risk to spread tumour cells and kill the
vast majority of patients within a ﬁve-year
period
1 and papillary thyroid carcinomas present-
ing low frequencies of clinically detectable distant
metastases even 10–20 years after diagnosis of the
primary tumour which is also related to a favour-
able prognosis.
2
One of the highly signiﬁcant differences of these
two tumour types is the degree of genomic instabil-
ity with more or less all of the pancreatic carcinomas
showingpronounced genomicinstability
3andmore
or less all of the papillary carcinomas presenting
a low degree of genomic instability at the time of
diagnosis.
4
Other types of malignancies, e.g. breast and
prostate carcinomas, can be subdivided into two
main groups which are characterized by either a
high or low degree of genomic instability
5,6
which in turn is strongly correlated to clinical
aggressiveness and patient survival.
Taken together, these data indicate that distant
metastases occur in both highly and lowly aggres-
sive cancer variants but that the time period from
diagnosis of the primary tumour to the clinical
occurrence of distant metastases, in turn deter-
mining patient survival, can differ signiﬁcantly.
This difference in growth activity contributes
that disseminated cancer cells – both local and
distant – are frequently not diagnosed resulting
in inadequate treatment decisions. Thus, tumour
cell dissemination either occurring spontaneously
during tumour progression or caused by, for
example, diagnostic needle or surgical biopsy
seems to be an under-estimated risk factor
especially in the patient group with tumours exhi-
biting a low degree of genomic instability.
In the present work we mainly focused on the
phenomenon of local tumour spreading and how
this serious complication of cancer disease can
be counteracted.
Diagnostic needle biopsy
procedures
Achieving a decisive morphologic diagnosis is
compulsory when a patient presents an
unknown lesion. In a majority of cases needle
biopsies will be performed. Today needle biopsies
can be subdivided into ﬁne needle aspiration
biopsy (FNAB) and core needle biopsy (CNB) for
which methodologies and equipment differ sub-
stantially. FNAB relies solely on needles with a
diameter of 0.5–0.8 mm in order to aspirate repre-
sentative malignant single cells or cell complexes
whereas CNB utilizes needles in the range of
1.2–3 mm or more to cut blocks of tissue from
the suspicious lesion. FNAB is considered to be
the less invasive and more patient-friendly
method.
7–9 Certain advantages of CNB, however,
namely the possibility to acquire preoperative
information on the state of invasion, histological
grade and receptor status have lead to CNB being
the method of choice in most malignancies.
Numerous case reports of malignant needle track
seeding have been published for different
tumours
10–14 and increasing caution is observed
in highly aggressive malignancies, e.g. in the
pancreas.
15
It has also been shown that tumour manipu-
lation during breast cancer surgery results in
tumour cell dissemination into the vascular circu-
lation.
16 A high count of CTC in peripheral blood
was found to decrease breast cancer patient survi-
val.
17 However, it is difﬁcult to determine the true
incidence of tumour cell dissemination in biopsy
procedures. From the time of tumour cell spread
until the development of clinically detectable
metastases, several years can elapse and the
detected lesions are indistinguishable from those
occurring spontaneously. Tracing needle channels
in surgically removed organs containing only
parts of the track is difﬁcult. Furthermore the
task is complicated by postoperative treatment,
e.g. radiotherapy and drugs reducing relapse
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2due to spontaneous spread or induced by the
biopsy. At the time of diagnosis some tumours
have not yet established cellular alterations inevi-
tably necessary for local or distant tumour growth.
However, there are tumour subgroups which at
the earliest clinically detectable stage have
already gained metastasizing properties and in
which the biopsy induced dissemination of
tumour cells may have implications on patient
survival. At present these subgroups cannot be
identiﬁed by non-invasive, for example imaging,
methods but only by morphological, immuno-
chemical or preferentially molecular analysis of
the tumour cells.
Platelets and cancer
Several studies have shown that cancer cells
receive a helping hand from platelets that protect
and feed disseminated tumour cells, making it
easier for cancer to metastasize. However, the
role of platelets in the biopsy procedure has yet
to be determined. Dislocated tumour cells that
are spread locally or into the periphery could
become more resistant to the immune system by
acquiring a protective coat of platelets.
18 Since
platelets seem to protect and growth stimulate dis-
seminated tumour cells it can be suggested that
the presently used traumatic diagnostic cell and
tissue biopsy procedures, causing bleeding in
association with biopsy-related blood vessel
injury, may initiate tumour cell spread of a still
local tumour disease.
Materials and Methods
In two consecutive materials of breast cancer
patients, one from 1991 (n= 519) and another
one from 1997–1998 (n =345), we have analysed
patients who died because of their breast cancer
and patients who died of cardio-cerebral-vascular
disease (CCVD). All data concerning cause of
death were retrieved from the Swedish Cause of
Death Register and are shown in Table 1. The
primary morphologic diagnosis in all patients
was based on FNAB technique and was conﬁrmed
histopathologically in material from the operated
breast. Since there were no known differences
between the two groups we could merge them
into one. The follow-up time in the material from
1991 and 1997–1998 was 17 and 10 years, respect-
ively. Multiple tumour disease parameters have
been analysed. In this report we focus on tumour
size, axillary lymph node metastases (ALNM)
and DNA index in breast cancer patients that
died either of their primary cancer or due to
CCVD. DNA index was based on the DNA
content of normal diploid epithelial cells. All
patients were treated according to standard
protocols based on clinical stadium and tumour
aggressiveness.
Statistical calculations were performed using
the STATISTICA software package (StatSoft,
Inc., Tulsa, OK, USA). Statistical signiﬁcance for
categorical variables was calculated using χ
2-test
and independent t-test was used for continu-
ous ones. Statistical signiﬁcance was assumed if
p <0.05.
Results
The two selected patient groups were statistically
inseparable with respect to tumour size and
DNA index, two objective parameters specifying
malignancy potential. In spite of this conformity,
the patient groups differed signiﬁcantly in
ALNM positivity. Patients in the group that died
of CCVD showed ALNM positivity in 27% of the
cases, as compared to 68% in the group that died
of the primary cancer (p <0.0001). We also
observed a signiﬁcantly increased survival time
in the CCVD patient group (102 months) com-
pared with patients who died of breast cancer
(61 months). Clinical and cytometric data of the
patients are shown in Table 2.
Table 1
Cause of death according to the Swedish Cause
of Death Register
Cause of
death
Patient material
from 1991
(n = 519)
Patient material
from 1997–1998
(n = 345)
Breast
cancer
147 52
CCVD 81 22
Other
types of
cancer
37 12
Others 34 14
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3Discussion
Dissemination of cancer cells followed by meta-
static growth is the most serious complication of
solid malignancies. Therefore, there is an urgent
need to introduce procedures making it possible
to prevent cancer cells from spreading. One well-
known efﬁcient course of action is early detection
and removal of the entire tumour when it is still in
the stage of in situ orearly locally invasive growth.
Other possible procedures are those that eliminate
the risk of tumour spread during diagnostic tissue
sampling and those preventing disseminated
tumour cells from surviving and growing. Since
only a minority of solid malignancies are detected
at the in situ or early locally invasive stage and the
fact that diagnostic needle or surgical biopsies are
generally necessary to obtain a ﬁnal pretreatment
diagnosis it is evident that techniques used
today are inappropriate to reach this goal. This is
clear from numerous studies reporting local
seeding in connection with diagnostic sampling
of tumour tissue.
10–15 A striking example is acom-
prehensive study of Hansen et al.
19 who showed
that preoperative manipulation of the primary
breast tumour using either FNAB or CNB tech-
niques resulted in an increase of sentinel node
metastases with as much as 50%.
I nt h ep r e s e n ts t u d yw ei n v e s t i g a t e dt h ei n c i -
dence of ALNM and patient survival in 864 breast
cancer patients who were preoperatively diagnosed
by means of FNAB, i.e. the most patient-friendly,
minimally traumatic sampling procedure. From
this patient cohort we selected those who died
because of their breast cancer disease and those
who died because of a simultaneously existing
CCVD, i.e. patients who at the time of FNAB
sampling and until death at least periodically were
exposed to anticoagulants. A decisive advantage
of the present study is that both the average size
and the DNA index of the primary breast cancers,
well known to be highly correlated to ALNM posi-
tivity and malignancy potential, were statistically
the same in the compared patient groups.
With this in mind, the highly signiﬁcant difference
(68% versus 27%) in ALNM positivity at the time
of diagnosis and survival time (61 versus 102
months) in the two patient categories indicate
that anticoagulant treatment seems to counteract
tumour cell seeding in turn improving patient
survival.
The data presented herein are in line with data
obtained from studies in cancer patients
20 and
experimental animals injected with highly malig-
nant tumour cells
21 showing that anticoagulants
counteract activation of platelets and by doing so
inhibit platelet-cancer cell interaction resulting in
reduced metastatic growth of disseminated
cancer cells.
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